Salubris shareholder plans stake reduction for personal capital needs

Shenzhen Salubris Pharmaceuticals announced that Shenzhen Runfu Investment Development Co., Ltd. ("Runfu"), a shareholder controlled by actual controller Chen Zhiming, plans to reduce its stake in the company. Runfu currently holds 15,465,952 shares, representing 1.39% of the total share capital. The proposed reduction involves up to 800,000 unrestricted circulating shares, which constitutes approximately 0.07% of the company's total share capital.

The share reduction will be executed through centralized bidding and/or block trading within three months from the announcement date, excluding periods restricted by law. The selling price will be determined by market prices at the time of sale. The primary reason for the reduction is personal capital needs of Cai Junfeng, a shareholder of Runfu and former deputy general manager and director of Salubris.

This planned reduction will not alter the company's control structure or impact its governance and operations. Salubris will continue to monitor the progress of this matter and ensure adherence to information disclosure obligations.